Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in the brain tissue to stop seizures.
Divalproex Sodium is also used to treat the manic phase of bipolar disorder (manic-depressive illness), and helps prevent migraine headaches.
This medicine is available only with your doctor's prescription.
Market Analysis and Insights: Global Divalproex Sodium Market
Due to the COVID-19 pandemic, the global Divalproex Sodium market size is estimated to be worth US$ 2188.5 million in 2021 and is forecast to a readjusted size of US$ 3350.9 million by 2028 with a CAGR of 6.2% during the forecast period 2022-2028.
North America is the largest market with about 41% market share. Europe is follower, accounting for about 26% market share.
The key players are AbbVie, Mylan, Zydus Pharms USA, Aurobindo Pharma, Dr Reddys Labs, LUPIN, Orchid, Sun Pharm, Teva etc. Top 3 companies occupied about 49% market share.
Global Divalproex Sodium Scope and Market Size
The global Divalproex Sodium market is segmented by region (country), company, by Type and by Application. Players, stakeholders, and other participants in the global Divalproex Sodium market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
Segment by Type
Tablet
Capsule
Others
Segment by Application
Epilepsy
Manic-depressive Illness
Others
By Company
AbbVie
Mylan
Zydus Pharms USA
Aurobindo Pharma
Dr Reddys Labs
LUPIN
Orchid
Sun Pharm
Teva
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E